BMS and Merck Buy Big Into Amphista’s Protein Degradation Platform with 2.3 Billion Collab
Summary : Bristol Myers Squibb and Merck KGaA are diving deeper into the protein degradation pool, with both inking partnerships with Amphista Therapeutics…
Summary : Bristol Myers Squibb and Merck KGaA are diving deeper into the protein degradation pool, with both inking partnerships with Amphista Therapeutics…